checkAd

     976  0 Kommentare AbbVie, Genomics Medicine Ireland and WuXi NextCODE Announce Landmark Population Genomics Alliance

    Effort will sequence the genomes of 45,000 participants from across Ireland to identify novel targets and advance the clinical development of better treatments for a range of serious diseases

    - Focus is on key AbbVie therapeutic areas including oncology, neuroscience and immunology

    Anzeige 
    Handeln Sie Ihre Einschätzung zu AbbVie!
    Long
    165,36€
    Basispreis
    1,58
    Ask
    × 9,05
    Hebel
    Short
    196,10€
    Basispreis
    1,60
    Ask
    × 8,93
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    - Genomics Medicine Ireland will partner with Ireland's leading clinicians and researchers and propel bioscience innovation in Ireland

    - WuXi NextCODE's integrated genomics platform will be used to organize and mine a secure, scalable database of whole genome sequence and medical data to power novel disease insights   

    NORTH CHICAGO, Illinois, DUBLIN and CAMBRIDGE, Massachusetts, Jan. 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, life-sciences startup Genomics Medicine Ireland Limited (GMI), and WuXi NextCODE, the global contract genomics organization, today announced the launch of a long-term strategic alliance to conduct population genomics research in Ireland aimed at advancing the discovery and development of novel therapeutic approaches to a range of serious diseases. The 15-year collaboration will focus on major chronic diseases within oncology, neuroscience and immunology that affect hundreds of thousands of people in Ireland and hundreds of millions worldwide.  Financial terms were not disclosed.

    WuXiNextCODE Leading Genomics

    The alliance will result in the sequencing of 45,000 genomes from volunteer participants across Ireland to seek novel insights into the biological processes that underlie complex disease. AbbVie will use the research database developed by GMI to identify new molecular approaches for therapeutic drug discovery and development as well as to develop companion diagnostics. The alliance builds on AbbVie's substantial existing presence in Ireland, which includes more than 600 employees and investments of more than $130 million since 2013.  

    "Genomics is transforming the way we understand some of the world's most devastating diseases and enabling the discovery of new approaches that have the potential to deliver much greater benefit to patients," said Jim Sullivan, Ph.D., vice president, pharmaceutical discovery, AbbVie. "This alliance is an important part of our research strategy and complements our significant footprint here in Ireland."

    Seite 1 von 3


    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    AbbVie, Genomics Medicine Ireland and WuXi NextCODE Announce Landmark Population Genomics Alliance Effort will sequence the genomes of 45,000 participants from across Ireland to identify novel targets and advance the clinical development of better treatments for a range of serious diseases - Focus is on key AbbVie therapeutic areas including …